Between January 2013 and March 2017, 1733 PIRADS-scored multiparametric MRI reports from a single radiologist in a prospective database were analyzed. 762 men subsequently underwent 806 transperineal template biopsies within 12 months of their MRI, with MRI-biopsy targeting performed in 45.3%. Their pathology reports were prospectively stored in the same database and used as the comparator. PIRADS scores of 4 or 5 were considered positive, and PIRADS scores of 1 or 2 considered negative. 96 PIRADS 3 scores, representing an equivocal result, were removed to yield 710 data points for sensitivity and specificity analysis.
The sensitivity and specificity results were 85.6% (95%CI: 81.80% to 88.94%) and 67.5% (95%CI: 61.99% to 72.73%) respectively, for the detection of clinically significant prostate cancer.
The authors concluded that increasing PIRADS scores correlated with both increased detection of clinically significant disease and higher grade groups.
Presented by: Miller R
Affiliation: Alfred Hospital, Monash University, Clayton, Australia
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal